The expression level of miR-155 in plasma and peripheral blood mononuclear cells in coronary artery disease patients and the associations of these levels with the apoptosis rate of peripheral blood mononuclear cells

Zhao,Duo; Zhao,Jing; Sun,Jiangbin; Su,Yanling; Jian,Jinfeng; Ye,Huaan; Lin,Jiawang; Yang,Zongda; Feng,Jiatao; Wang,Zhiping

doi:10.3892/etm.2018.6797

The expression level of miR-155 in plasma and peripheral blood mononuclear cells in coronary artery disease patients and the associations of these levels with the apoptosis rate of peripheral blood mononuclear cells

Authors:
- Duo Zhao
- Jing Zhao
- Jiangbin Sun
- Yanling Su
- Jinfeng Jian
- Huaan Ye
- Jiawang Lin
- Zongda Yang
- Jiatao Feng
- Zhiping Wang
View Affiliations

Affiliations: Department of Cardiovascular Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China, Department of Cardiovascular Surgery, The First People's Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), Foshan, Guangdong 528000, P.R. China, Department of Cardiovascular Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China
Published online on: September 26, 2018 https://doi.org/10.3892/etm.2018.6797
Pages: 4373-4378
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the study was to investigate the expression of miR-155 in plasma and peripheral blood mononuclear cells (PBMCs), the effects of miR-155 on the apoptosis rate of PBMCs and the extent of coronary stenosis in coronary artery disease patients. Seventy chest pain patients were divided into three groups by symptoms, signs, auxiliary examination and coronary arteriography: 21 cases in the acute myocardial infarction group (AMI), 23 cases in the Angor pectoris group (AP) and 26 cases in the control group (CT). The peripheral blood mononuclear cells of the patients in the three groups were separated for cell culture. Annexin V/propidium iodide (PI) was performed to analyze cell apoptosis. RT-qPCR was used to evaluate the expression level of miR-155 in plasma and PBMCs. There were significant differences on the expression of miR-155 in plasma and PBMCs, the apoptosis rate of PBMCs, Gensini score and the extent of coronary stenosis among the three groups (P<0.05). The expression of miR-155 in plasma and PBMCs in AMI and AP group were lower than CT group while the AMI group was lower than the AP group (P<0.05). The apoptotic rate of PBMCs, Gensini score and the extent of coronary stenosis of the AMI and AP groups were higher than CT group while the AMI group was higher than the AP group (P<0.05). The expression of miR-155 in plasma was positively correlated with PBMCs, but negatively correlated with the apoptosis rate of PBMCs, Gensini score and the extent of coronary stenosis. The apoptosis rate of PBMCs in patients with coronary heart disease was positively correlated with the degree of coronary artery stenosis and Gensini score. In conclusion, in the patients with coronary heart disease the apoptosis rate of PBMCs was increased and the expression of miR-155 in plasma and PBMCs cells was decreased, which were correlated with the severity of coronary heart disease.

View Figures

View References

1	Vasilets LM, Grigoriadi NE, Karpunina NS, Tuev AV and Rotanova EA: Immune status of patients with persistent atrial fibrillation and coronary heart disease. Klin Med (Mosk). 91:32–34. 2013.(In Russian). PubMed/NCBI
2	Zheng H, Tu Y and Teng ZH: Effect of immune response mediated by antigen-specific T cells on plaque stability in coronary heart disease. Nan Fang Yi Ke Da Xue Xue Bao. 301610–1611. (1614)2010.(In Chinese). PubMed/NCBI
3	Fu L, Jin L, Yan L, Shi J, Wang H, Zhou B and Wu X: Comprehensive review of genetic association studies and meta-analysis on miRNA polymorphisms and rheumatoid arthritis and systemic lupus erythematosus susceptibility. Hum Immunol. 77:1–6. 2016. View Article : Google Scholar : PubMed/NCBI
4	Mizuguchi Y, Takizawa T, Yoshida H and Uchida E: Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic review. Hepatol Res. 46:391–406. 2016. View Article : Google Scholar : PubMed/NCBI
5	Wen MM: Getting miRNA therapeutics into the target cells for neurodegenerative diseases: A Mini-Review. Front Mol Neurosci. 9:1292016. View Article : Google Scholar : PubMed/NCBI
6	Yu DD, Lv MM, Chen WX, Zhong SL, Zhang XH, Chen L, Ma TF, Tang JH and Zhao JH: Role of miR-155 in drug resistance of breast cancer. Tumour Biol. 36:1395–1401. 2015. View Article : Google Scholar : PubMed/NCBI
7	Lind EF and Ohashi PS: Mir-155, a central modulator of T-cell responses. Eur J Immunol. 44:11–15. 2014. View Article : Google Scholar : PubMed/NCBI
8	Vigorito E, Kohlhaas S, Lu D and Leyland R: miR-155: An ancient regulator of the immune system. Immunol Rev. 253:146–157. 2013. View Article : Google Scholar : PubMed/NCBI
9	Zhu GF, Yang LX, Guo RW, Liu H, Shi YK, Ye JS and Yang ZH: microRNA-155 is inversely associated with severity of coronary stenotic lesions calculated by the Gensini score. Coron Artery Dis. 25:304–310. 2014. View Article : Google Scholar : PubMed/NCBI
10	Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Röxe T, Müller-Ardogan M, et al: Circulating microRNAs in patients with coronary artery disease. Circ Res. 107:677–684. 2010. View Article : Google Scholar : PubMed/NCBI
11	Zhang YH, Xia LH, Jin JM, Zong M, Chen M and Zhang B: Expression level of miR-155 in peripheral blood. Asian Pac J Trop Med. 8:214–219. 2015. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Wirtz PH and von Känel R: Psychological stress, inflammation, and coronary heart disease. Curr Cardiol Rep. 19:1112017. View Article : Google Scholar : PubMed/NCBI
14	He LY, Zhao JF, Han JL, Shen SS and Chen XJ: Correlation between serum free fatty acids levels and Gensini score in elderly patients with coronary heart disease. J Geriatr Cardiol. 11:57–62. 2014.PubMed/NCBI
15	Che J, Li G, Wang W, Li Q, Liu H, Chen K and Liu T: Serum autoantibodies against human oxidized low-density lipoproteins are inversely associated with severity of coronary stenotic lesions calculated by Gensini score. Cardiol J. 18:364–370. 2011.PubMed/NCBI
16	Jia QW, Chen ZH, Ding XQ, Liu JY, Ge PC, An FH, Li LH, Wang LS, Ma WZ, Yang ZJ, et al: Predictive effects of circulating miR-221, miR-130a and miR-155 for coronary heart disease: A multi-ethnic study in China. Cell Physiol Biochem. 42:808–823. 2017. View Article : Google Scholar : PubMed/NCBI
17	Zhu J, Chen T, Yang L, Li Z, Wong MM, Zheng X, Pan X, Zhang L and Yan H: Regulation of microRNA-155 in atherosclerotic inflammatory responses by targeting MAP3K10. PLoS One. 7:e465512012. View Article : Google Scholar : PubMed/NCBI
18	Tian FJ, An LN, Wang GK, Zhu JQ, Li Q, Zhang YY, Zeng A, Zou J, Zhu RF, Han XS, et al: Elevated microRNA-155 promotes foam cell formation by targeting HBP1 in atherogenesis. Cardiovasc Res. 103:100–110. 2014. View Article : Google Scholar : PubMed/NCBI
19	Pan RY, Liu P, Zhou HT, Sun WX, Song J, Shu J, Cui GJ, Yang ZJ and Jia EZ: Circular RNAs promote TRPM3 expression by inhibiting hsa-miR-130a-3p in coronary artery disease patients. Oncotarget. 8:60280–60290. 2017. View Article : Google Scholar : PubMed/NCBI
20	Farrokhian A, Raygan F, Soltani A, Tajabadi-Ebrahimi M, Esfahani Sharifi M, Karami AA and Asemi Z: The effects of synbiotic supplementation on carotid intima-media thickness, biomarkers of inflammation, and oxidative stress in people with overweight, diabetes, and coronary heart disease: A randomized, double-blind, placebo-controlled trial. Probiotics Antimicrob Proteins. Oct 27–2017.(Epub ahead of print). doi: 10.1007/s12602-017-9343-1. View Article : Google Scholar : PubMed/NCBI
21	Louafi F, Martinez-Nunez RT and Sanchez-Elsner T: MicroRNA-155 targets SMAD2 and modulates the response of macrophages to transforming growth factor-{beta}. J Biol Chem. 285:41328–41336. 2010. View Article : Google Scholar : PubMed/NCBI
22	Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF and Wang ED: MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 70:3119–3127. 2010. View Article : Google Scholar : PubMed/NCBI